Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Than Half Of Erectile Dysfunction Drugs Sold Online In Japan Fakes

This article was originally published in PharmAsia News

Executive Summary

A survey revealed that over 55 percent of erectile dysfunction drugs sold over the internet targeting Japanese customers are counterfeits. Conducted from December 2008 to April 2009, the survey is a joint project of four drug makers of Viagra (sildenafil), Levitra (vardenafil) and Cialas (tadalafil): Pfizer, Bayer Yakuhin, Eli Lilly Japan and Nippon Shinyaku. The companies analyzed drug samples ordered from 30 websites that are based in domestic locations and 30 sites in Thailand targeting Japanese customers. The results show that the majority of the counterfeits are imports from Thailand, accounting for 67.8 percent, and fake ED drugs purchased inside Japan account for 43.6 percent. The quality of the counterfeits also vary; some contain more or less active ingredients and others have no active ingredients at all. (Click here for more - Japanese language

You may also be interested in...



Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.

QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.

Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel